According to Novo's official account, Novo Zhiyuan signed an in-depth cooperation agreement with Qijia Technology Co., Ltd. on October 19. The two sides will establish a long-term cooperative relationship around “multiomics capability+organoid model”, focusing on promoting the construction of multi-omics standards for organoid physiological models, development of reference systems for pathological models, joint R&D projects, and exploration of traditional Chinese medicine organ evaluation standards, to jointly enhance the scientific nature, interpretability and industrial-grade deliverability of organoid evaluations, and provide overall organoid solutions closer to human physiological characteristics for new drug research and development, disease mechanism research, and precision medicine.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.